Financial
FY2025 revenue $44.33bn (+5.7%); operating margin 18.2%; net income $6.52bn.
Balance sheet figures not captured from release.
Abbott
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: ABT
FY2025 revenue $44.33bn (+5.7%); operating margin 18.2%; net income $6.52bn.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$44.3bn | +5.7% | US$8.1bn | US$6.5bn | Abbott Laboratories |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Mar 2026: Abbott completed its acquisition of Exact Sciences, adding cancer screening and diagnostics such as Cologuard; the acquired business was later the subject of a cyber incident (see Cyber & information governance).
Cyber & information governance
Jul 2026: Abbott confirmed unauthorised access to a limited number of legacy Exact Sciences systems in its Cancer Diagnostics business and investigated a potential incident on its LabCentral portal; hackers claimed large data theft, which Abbott has not confirmed. NHS DSPT status not yet checked.
Regulatory & clinical safety
Dec 2025: millions of FreeStyle Libre 3 and Libre 3 Plus glucose sensors were recalled over faulty low readings, which the FDA linked to seven deaths and hundreds of serious injuries worldwide.
Contract performance
No notable NHS contracts, troubled implementations, disputes or terminations involving Abbott found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.